Insignificant systemic exposure. The substance is not metabolised and does not interact with CYPs.

(To be edited, initial data ST OCT 04) Antiviral neuramidase inhibitor used (inhalation 2x5 mg twice daily for 5 days) in symptomatic influenza A and B in adults and children > 12 years. The dose is deposited (about 80%) in oropharynx. Eliminated from there to the gastrointestinal tract with bioavailability of only 2 %. No metabolism takes place. No interaction with the metabolism of other drugs is observed.